古塞奇尤单抗在中重度斑块状银屑病亚组患者中的疗效:VOYAGE 1和VOYAGE 2 III期研究的汇总分析
该汇总分析基于VOYAGE 1和VOYAGE 2两项III期研究,纳入1829例中重度斑块状银屑病患者,评估古塞奇尤单抗在不同亚组中的疗效一致性。结果显示,古塞奇尤单抗在几乎所有亚组中均较安慰剂(第16周)和阿达木单抗(第24周)有更高比例患者达到IGA 0/1,且在体重≥100 kg患者中优势更明显。
要点
- 古塞奇尤单抗在多数亚组中第16周IGA 0/1优于安慰剂。
- 第24周古塞奇尤单抗IGA 0/1和IGA 0优于阿达木单抗。
- 体重≥100 kg患者中古塞奇尤单抗疗效优势更明显。
核心结论
- 古塞奇尤单抗在不同基线人口学、疾病特征及既往治疗的中重度斑块状银屑病亚组中均显示高度疗效。
研究设计与样本
- 汇总VOYAGE 1和VOYAGE 2两项III期研究,共随机1829例中重度斑块状银屑病患者。
主要发现
- 第16周,古塞奇尤单抗组达到IGA 0/1的患者比例高于安慰剂组。
- 第24周,古塞奇尤单抗组达到IGA 0/1和IGA 0的患者比例高于阿达木单抗组。
- 在所有体重四分位组中,第24周古塞奇尤单抗疗效均优于阿达木单抗,体重≥100 kg患者中尤为明显。
临床怎么用
- 对于中重度斑块状银屑病患者,古塞奇尤单抗在不同亚组中均可考虑使用。
- 体重≥100 kg的患者可能从古塞奇尤单抗治疗中获得更明显获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Significant advances have been made in the treatment of moderate-to-severe plaque psoriasis with biological therapies; however, these agents may not work equally in all populations. OBJECTIVES: To evaluate the efficacy of guselkumab in patient subgroups with moderate-to-severe psoriasis from the pooled guselkumab VOYAGE 1 and VOYAGE 2 phase III studies. METHODS: Using data from the pooled VOYAGE 1 and VOYAGE 2 psoriasis studies, analyses were performed to evaluate the consistency of efficacy [Investigator's Global Assessment (IGA) 0/1 (cleared or minimal psoriasis) and IGA 0 (cleared)] across subpopulations defined by demographics, baseline disease characteristics and previous psoriasis treatment. RESULTS: A total of 1829 patients were randomized. Baseline demographics, disease characteristics and previous psoriasis treatment were comparable across treatment groups in the pooled population. Guselkumab, an anti-interleukin (IL)-23 monoclonal antibody that binds to the p19 subunit of IL-23, provided substantial benefit across almost all subpopulations, with greater proportions of patients achieving IGA 0/1 vs. placebo at week 16, and vs. adalimumab (an antitumour necrosis factor monoclonal antibody) at week 24. Patients treated with guselkumab achieved greater efficacy (IGA 0/1 and IGA 0) compared with adalimumab at week 24 across all weight quartiles, most notably among patients weighing ≥ 100 kg. CONCLUSIONS: This analysis demonstrates a high degree of efficacy with guselkumab treatment compared with placebo at week 16 and with adalimumab at week 24 among broad subpopulations of patients with varying baseline demographics, disease characteristics and previous psoriasis treatments.
引用
- Gordon KB, Blauvelt A, Foley P, et al. Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies. Br J Dermatol. 2017. PMID: 28940259. doi:10.1111/bjd.16008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。